Multiple Transplantation of Bone Marrow Derived CD133 Cell in Cerebral Palsy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Cerebral palsy (CP) is condition, sometimes thought of as a group of disorders that can involve brain and nervous system functions such as movement, learning, hearing, seeing, and thinking.Cerebral palsy is caused by injuries or abnormalities of the brain. Most of these problems occur as the baby grows in the womb, but they can happen at any time during the first 2 years of life, while the baby's brain is still developing.Bone marrow derived stem cells are known as a effective therapy.
In this study the investigators evaluate the side effect of multiple intrathecal injection of bone marrow stem cell in patients with cerebral palsy.
| Condition | Intervention | Phase |
|---|---|---|
|
Cerebral Palsy |
Biological: stem cell intrathecal injection |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Safety of Multiple Intrathecal Injection of Bone Marrow Derived CD133 Cells in Patients With Cerebral Palsy |
- motor dysfunction [ Time Frame: 6months ] [ Designated as safety issue: Yes ]Evaluation the motor dysfunction 6months after intrathecal injection.
- sensory dysfunction [ Time Frame: 6months ] [ Designated as safety issue: Yes ]Evaluation the sensory dysfunction after intrathecal injection of CD133 cells.
- unconsciousness [ Time Frame: 48hours ] [ Designated as safety issue: Yes ]Evaluation the rate of unconsciousness during 48hours after cell transplantation.
- fever [ Time Frame: 48hours ] [ Designated as safety issue: Yes ]Evaluation the symptom of infection like fever 48hours after cell transplantation.
- motor improvement [ Time Frame: 6months ] [ Designated as safety issue: No ]Measure the improvement of motor system by GMFM66.
- Balance improvement [ Time Frame: 6months ] [ Designated as safety issue: No ]Measure the balance improvement by BBS.
- Spasm [ Time Frame: 6months ] [ Designated as safety issue: No ]Evaluation the improvement of spasm after stem cell transplantation.
| Estimated Enrollment: | 24 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: CD133 transplantation
The patients with cerebral palsy that underwent CD133 transplantation.
|
Biological: stem cell intrathecal injection
Intrathecal injection of Bone marrow derived CD133 cells
Other Name: Stem cell transplantation
|
|
No Intervention: Control
The patients with cerebral palsy that underwent regular observation.
|
Detailed Description:
In this study,we evaluate the safety of multiple transplantation of bone marrow derived stem cells.the children(4-12years)with definite diagnose of cerebral palsy enroll to the study.first of all all the physical exam,laboratory test,EEG and MRI is done.after hospital admission,the patient underwent bone marrow transplantation.In laboratory,the cells are separated and prepared for injection.after 24hours the neurosurgeon inject the cells(intrathecal).the patient would be under observed for 48hours.If no allergic reaction or abnormal neurological symptoms accrued,patients can be discharged and would be followed up 1,3 and 6months after injection.at the end of the 6months,the patients would receive second injection as same as the previous process.then they are followed at 1,3 immediate local and systemic side effect(fever,respiratory distress,erythema,rash,increase of heart rate or blood pressure)and neurological symptoms:motor dysfunction,sensory dysfunction,sphincter dysfunction,nausea,vomiting,head ache.EEG,MRI,GMFM66
Eligibility| Ages Eligible for Study: | 4 Years to 12 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosis of spastic quadriplegic CP Children must be between the ages of 4 and 12 years Children must be cleared by an orthopedic surgeon for risk of hip subluxation or dislocation and cannot have significant scoliosis (curvature > 40 degrees) Children must be seizure-free or seizure controlled
Exclusion Criteria:
- Children who have a diagnosis of "mixed" types of CP (i.e. athetosis) or other movement disorders (i.e. ataxia) Children who have had a selective dorsal rhizotomy, are presently are receiving intrathecal Baclofen, or have changed their spasticity medications in the past 6 months.
Children who have a metallic or electrical implants
Contacts and Locations| Contact: Nasser Aghdami, MD,PhD | +9821235622000 ext 504 | nasser.aghdami@royaninstitute.org |
| Contact: Leila Arab, MD | +982123562000 ext 414 | leara91@gmail.com |
| Iran, Islamic Republic of | |
| Royan Institute | Recruiting |
| Tehran, Iran, Islamic Republic of | |
| Contact: Nasser Aghdami, MD,PhD +982123562000 ext 504 nasser.aghdami@royaninstitute.org | |
| Contact: Leila Arab, MD +982123562000 ext 414 leara91@gmail.com | |
| Principal Investigator: Leila Arab, MD | |
| Principal Investigator: Farzad Ashraafi, MD | |
| Sub-Investigator: Soura Mardpour, MSc | |
| Sub-Investigator: Vagihe Azimian, PhD student | |
| Study Chair: | Hamid Gourabi, PhD | Head of Royan Institute |
| Study Director: | Nasser Aghdami, MD,PhD | Head of Royan department of degenerative medicine,Head of Royan celltherapy center |
| Study Director: | Ali Reza Zali, MD | Head of Neurosurgery research center of Shahid Beheshti University |
More Information
Additional Information:
No publications provided
| Responsible Party: | Royan Institute |
| ClinicalTrials.gov Identifier: | NCT01763255 History of Changes |
| Other Study ID Numbers: | Royan-Nerve-003 |
| Study First Received: | December 25, 2012 |
| Last Updated: | March 13, 2013 |
| Health Authority: | Iran: Ethics Committee Iran: Ministry of Health |
Keywords provided by Royan Institute:
|
cerebral palsy CD133 cells intrathecal injection |
Additional relevant MeSH terms:
|
Cerebral Palsy Paralysis Brain Damage, Chronic Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013